Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

Publication Type:

Journal Article

Source:

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 26, Issue 15, p.2450-6 (2008)

Keywords:

2008, ADENOCARCINOMA, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Cisplatin, Combined Modality Therapy, Etoposide, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Staging, Prognosis, Public Health Sciences Division, Quinazolines, Remission Induction, Survival Rate, Taxoids

Abstract:

Early clinical studies with gefitinib showed promising efficacy and mild toxicity in patients with advanced non-small-cell lung cancer (NSCLC). Thus, gefitinib was an ideal agent to evaluate in a maintenance setting in stage III disease.